p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial

A Leo, M Tanner, C Desmedt, J Isola

Research output: Contribution to journalArticleScientificpeer-review

50 Citations (Scopus)
Original languageEnglish
Pages (from-to)997-1003
JournalAnnals of Oncology
Issue number6
Publication statusPublished - 2007
Publication typeA1 Journal article-refereed

Cite this